Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

706
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
706
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

455
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

698
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
698
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

530
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
530

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

QutRNA2: robust tRNA modification discovery from Nanopore direct tRNA sequencing.

NAR genomics and bioinformatics·2026
Same author

Sequential changes in calcium transients during M phase regulate cardiomyocyte proliferation.

The Journal of cell biology·2026
Same author

<i>Kbtbd13</i> knockdown restores muscle function in a clinically relevant mouse model of nemaline myopathy type 6.

Science translational medicine·2026
Same author

Circtools 2.0: a comprehensive framework for enhanced circular RNA bioinformatics.

BMC bioinformatics·2026
Same author

Targeting intracellular cholesterol imbalance rescues sarcomere-ER contact site signaling and ER remodeling in dilated cardiomyopathy.

Signal transduction and targeted therapy·2026
Same author

The SURROGATOR Framework for Context-Aware Surrogation of Privacy Sensitive Information in Medical Text.

Studies in health technology and informatics·2026

Related Experiment Video

Updated: Mar 11, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.6K

Reducing RBM20 activity improves diastolic dysfunction and cardiac atrophy.

Florian Hinze1,2, Christoph Dieterich3,4, Michael H Radke1,2

  • 1Neuromuscular and Cardiovascular Cell Biology, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125, Berlin, Germany.

Journal of Molecular Medicine (Berlin, Germany)
|November 28, 2016
PubMed
Summary

Reducing RBM20 activity in mice with diastolic dysfunction maintained cardiac filling and improved heart function. This suggests targeting cardiac splicing, specifically RBM20, is a promising therapeutic strategy for heart failure with preserved ejection fraction.

Keywords:
Heart failureHypertrophy signalingMouse modelsRNA processingTherapy

More Related Videos

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.6K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.6K

Related Experiment Videos

Last Updated: Mar 11, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.6K
Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.6K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.6K

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Diastolic dysfunction, characterized by impaired diastolic filling, is a primary driver of heart failure with preserved ejection fraction (HFpEF).
  • Titin, a giant sarcomeric protein, significantly influences diastolic function through its elastic properties.
  • Current therapeutic options for HFpEF remain limited, highlighting the need for novel treatment strategies.

Purpose of the Study:

  • To investigate titin-based stiffness as a potential therapeutic target for diastolic dysfunction.
  • To evaluate the impact of modulating RBM20-dependent cardiac titin isoform expression on cardiac function in a mouse model.

Main Methods:

  • Utilized a titin N2B knockout mouse model exhibiting increased ventricular stiffness.
  • Adjusted RBM20-dependent cardiac titin isoform expression, achieving approximately a 50% reduction in RBM20 activity.
  • Analyzed cardiac filling, cardiac atrophy, cardiac function, gene expression (muscle development, fatty acid metabolism), and hypertrophy signaling via four-and-a-half lim-domain proteins (FHLs).

Main Results:

  • Reduced RBM20 activity maintained diastolic cardiac filling in the N2B-deficient heart.
  • This intervention ameliorated cardiac atrophy and improved overall cardiac function.
  • Gene expression related to muscle development and fatty acid metabolism was partially normalized, and cardiac growth adaptation involved FHL-mediated hypertrophy signaling.

Conclusions:

  • Modulating RBM20 activity represents a novel therapeutic approach for diastolic dysfunction.
  • Cardiac splicing, influenced by RBM20, offers a potential target for treating HFpEF.
  • A link was established between cardiac isoform expression, FHL-mediated trophic signaling, and diastolic dysfunction treatment.